PA
VNDA icon

Perceptive Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Perceptive Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100,000
Closed -$930K – 188
2015
Q1 		$930K Sell
100,000
-500,000
-83% -$5.65M 0.07% 104
2014
Q4 		$8.59M Buy
+600,000
New +$7.1M 0.72% 34
2013
Q4 		– Sell
-482,600
Closed -$5.28M – 131
2013
Q3 		$5.28M Buy
+482,600
New +$5.16M 0.43% 40

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's VNDA Position: Q4 2017 in Review

Perceptive Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 36,232 shares — an estimated $649K sold.

Perceptive Advisors first reported a position in VNDA in Q3 2013 and held it in 6 quarters. The position peaked at $9.51M in Q3 2013. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • Perceptive Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 36,232 Vanda Pharmaceuticals shares in Q4 2017, an estimated $649K.
  • Perceptive Advisors first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Perceptive Advisors's Vanda Pharmaceuticals position peaked at $9.51M in Q3 2013.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.